Moderna wins FDA approval for 2026-2027 COVID-19 vaccine updates targeting XFG subvariant
MRNA•FDA clears updated Spikevax and mNEXSPIKE shots
Moderna secured FDA clearance for 2026-2027 versions of Spikevax and mNEXSPIKE targeting the JN.1-lineage XFG subvariant.
- Spikevax covers high-risk patients ages 6 months-64 years, and all adults 65+.
- mNEXSPIKE covers high-risk patients ages 12-64, and all adults 65+.
- Updated shots are expected to reach the US market in the coming days.
